High volume in calls accompanied by higher prices in the call indicates informed traders think good news may be announced.
bought this baby $$
Major Stock Indexes Trade Down About 2%
Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting
| 01/15/16 - 09:29 AM EST
Exclusive FREE Report: Jim Cramer's Best Stocks for 2016
Sarepta Therapeutics' (SRPT) stock price plummeted Friday on a very negative clinical review of the company's Duchenne muscular dystrophy drug eteplirsen released by the U.S. Food and Drug Administration
Jefferies Biotech Stock to Buy for 2016 With Huge Upside Potential
By Lee Jackson January 15, 2016
Jefferies feels this large cap stock also has solid upside potential for 2016. Celgene Corp. (NASDAQ: CELG) has an outstanding partnered pipeline, which most think is low risk and has the potential to yield several blockbuster drugs.
The company provided strong guidance last year on its Otezla launch and encouraging feedback from doctors on the potential of new triplet regimens in myeloma. Analysts across Wall Street raised their estimates for the drug as, after a little more than a year and a half on the market, Otezla which treats psoriasis and psoriatic arthritis, has achieved considerable prescriptions among physicians.
Celgene’s blockbuster blood cancer drug Revlimid continues to dominate. Pomalyst sales also continue to be solid. Cancer drug Abraxane is also growing at a respectable rate, so the company continues to have a strong lineup of top-selling drugs. The stock jumped recently when Celgene and Natco came to a patent settlement, which removes a huge overhang on the stock that has been there for some time. Revlimid makes up over 60% of the company’s total revenue, so having better clarity on the duration of its life cycle should continue to be a positive in 2016 and beyond. The Jefferies price target is raised to $149.
lululemon athletica inc. Updates Guidance for Fourth Quarter of Fiscal 2015 Ahead of Presentation at the ICR Conference